Rachel Lamparelli focuses her practice on matters relating to the US Food and Drug Administration (FDA) and life sciences industry as well healthcare transactional, regulatory, and compliance matters for a broad range of healthcare providers including pharmacies, hospices, hospitals, and physician practices. Rachel has experience with False Claims Act and Anti-Kickback Statute investigations and counseling, Medicare and Medicaid reimbursement and compliance, physician contracting, and state licensing and other regulatory matters.
Rachel has experience representing private equity and financial investor clients in mergers and acquisitions (M&A), including performing healthcare regulatory due diligence and advising on change of ownership issues. Rachel has also assisted with numerous multistate and 50-state surveys on subjects such as scope of practice, supervision and delegation, change of ownership and change of information, asynchronous telehealth, prescription drug discounts and pricing, and wholesale drug distribution.
Rachel earned her J.D. from Case Western Reserve University School of Law, followed by an M.P.H. from Johns Hopkins Bloomberg School of Public Health. During her master’s, Rachel served as an intern for the US House of Representatives Committee on Oversight and Government Reform. While attending law school, Rachel was the executive articles editor for Case Western Reserve Law Review.